Link to full page (citation export, more details):
Full Text PDF:
SI PDF:
Journal: ACS Bio. Med. Chem. Au
Year: 2023
Volume: 4
Issue: 2
Pages: 100-110
DOI: 10.1021/acsbiomedchemau.3c00030
Type of Publication: Journal Article
Keywords:
docking; Drug Discovery; enzymatic assay; epitranscriptomics; m7G writer; MD simulation
Abstract:
We discovered the first inhibitors of the m7G-RNA writer METTL1 by high-throughput docking and an enzymatic assay based on luminescence. Eleven compounds, which belong to three different chemotypes, show inhibitory activity in the range 40-300uM Two adenine derivatives identified by docking have very favorable ligand efficiency of 0.34 and 0.31 kcal/mol per non-hydrogen atom, respectively. Molecular dynamics simulations provide evidence that the inhibitors compete with the binding of the cosubstrate S-adenosylmethionine to METTL1. We also present a soakable crystal form that was used to determine the structure of the complex of METTL1 with sinefungin at a resolution of 1.85A.